Cyclerion Therapeutics (NASDAQ:KRSA) Coverage Initiated by Analysts at Wedbush

Wedbush initiated coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research report released on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $44.00 target price on the stock.

A number of other equities research analysts have also weighed in on KRSA. Stifel Nicolaus began coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating and a $43.00 target price on the stock. TD Cowen initiated coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They set a “buy” rating for the company. Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. Guggenheim initiated coverage on Cyclerion Therapeutics in a research report on Monday, September 28th. They issued a “buy” rating and a $70.00 price target for the company. Finally, Wall Street Zen upgraded shares of Cyclerion Therapeutics to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $53.00.

Cyclerion Therapeutics Stock Up 0.8%

Shares of NASDAQ KRSA opened at $30.72 on Monday. The stock has a market cap of $20.58 million, a PE ratio of -2.64 and a beta of 1.72. Cyclerion Therapeutics has a 1 year low of $7.19 and a 1 year high of $59.36.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.